Free Trial

4basebio (4BB) Competitors

4basebio logo
GBX 1,110 -40.00 (-3.48%)
As of 09:50 AM Eastern

4BB vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, AVCT, CIR, and BVXP

Should you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Avacta Group (AVCT), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.

4basebio vs.

4basebio (LON:4BB) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Silence Therapeutics received 202 more outperform votes than 4basebio when rated by MarketBeat users. However, 100.00% of users gave 4basebio an outperform vote while only 68.81% of users gave Silence Therapeutics an outperform vote.

CompanyUnderperformOutperform
4basebioOutperform Votes
1
100.00%
Underperform Votes
No Votes
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%

In the previous week, 4basebio had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Silence Therapeutics. 4basebio's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company Overall Sentiment
4basebio Neutral
Silence Therapeutics Neutral

Silence Therapeutics' return on equity of 0.00% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Silence Therapeutics N/A N/A N/A

Silence Therapeutics has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£311K473.68-£9.84M-£0.78-1,474.36
Silence Therapeutics£11.35M0.00N/A-£48.60N/A

2.0% of 4basebio shares are owned by institutional investors. 68.4% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

4basebio presently has a consensus target price of GBX 1,600, indicating a potential upside of 39.13%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

4basebio beats Silence Therapeutics on 8 of the 13 factors compared between the two stocks.

Remove Ads
Get 4basebio News Delivered to You Automatically

Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

4BB vs. The Competition

Metric4basebioBiotechnology IndustryMedical SectorLON Exchange
Market Cap£147.32M£109.40M£5.63B£2.58B
Dividend YieldN/A3.78%5.33%4.82%
P/E Ratio-1,474.363.1023.61141.64
Price / Sales473.684,225.22384.78273,878.92
Price / Cash16.0812.7538.1728.13
Price / Book-28.0536.246.874.54
Net Income-£9.84M-£91.48M£3.20B£5.81B
7 Day Performance5.22%-2.40%-3.57%0.69%
1 Month Performance-0.86%59.21%1.50%6.70%
1 Year Performance19.79%82.96%9.09%30.45%

4basebio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
4BB
4basebio
1.7649 of 5 stars
GBX 1,110
-3.5%
GBX 1,600
+44.1%
+19.8%£142.19M£311,000.00-1,423.08101High Trading Volume
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
1.8468 of 5 stars
GBX 127.60
flat
GBX 455
+256.6%
-33.8%£383.29M£521,320.79-5.23300Positive News
OXB
Oxford Biomedica
2.5241 of 5 stars
GBX 305
+1.2%
GBX 560
+83.6%
+54.7%£324.22M£98.31M-2.27891
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 191.69
+0.9%
N/A+47.5%£257.34MN/A-5.1334News Coverage
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
AVCT
Avacta Group
N/AGBX 39.65
+5.0%
N/A-20.7%£150.62M£26.29M-5.10120
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,630
-0.8%
N/A-38.4%£137.72M£13.65M17.0112
Remove Ads

Related Companies and Tools


This page (LON:4BB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners